文献速递神经免疫

多发性硬化患者使用芬戈莫德、那他珠单抗与利妥昔单抗的癌症风险

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
PubMed 文献 · Ann Neurol · 2020-03-09

该研究基于瑞典多发性硬化登记等全国登记数据,纳入利妥昔单抗、芬戈莫德、那他珠单抗首次启用共4187、1620、1670例次及按年龄性别地区匹配的37801名非多发性硬化普通人群,比较首次浸润性癌症发生时间。利妥昔单抗与那他珠单抗相对普通人群未见浸润性癌症风险升高,芬戈莫德相对普通人群及利妥昔单抗呈边缘显著性风险升高,尚不能归因于特定癌种。

要点

  • 利妥昔单抗与那他珠单抗相较普通人群未见浸润性癌症风险升高。
  • 芬戈莫德相较普通人群及利妥昔单抗呈边缘显著性癌症风险升高。
  • 该风险升高无法归因于任何特定类型癌症,需进一步研究验证。

核心结论

  • 在3种高效多发性硬化疾病修饰治疗的大型对比研究中,利妥昔单抗和那他珠单抗相较普通人群未见浸润性癌症风险增加。
  • 芬戈莫德相较普通人群和利妥昔单抗呈边缘显著性浸润性癌症风险升高。
  • 该风险升高无法归因于任何特定类型癌症,需进一步研究验证。

研究设计与样本

  • 全国性登记队列研究,将瑞典多发性硬化登记与瑞典癌症登记及其他全国医疗和人口普查登记链接。
  • 纳入6136例多发性硬化患者中利妥昔单抗首次启用4187例次、芬戈莫德1620例次、那他珠单抗1670例次。
  • 按年龄、性别和地区匹配37801名非多发性硬化普通人群受试者。
  • 主要结局为至首次浸润性癌症的时间。

主要发现

  • 治疗患者中共识别78例浸润性癌症:利妥昔单抗33例(发病率每万人年34.4,95%CI 23.7-48.3)。
  • 芬戈莫德28例(发病率每万人年44.0,95%CI 29.2-63.5),那他珠单抗17例(发病率每万人年26.0,95%CI 15.1-41.6)。
  • 普通人群发病率为每万人年31.0(95%CI 27.8-34.4)。
  • 调整基线特征后,利妥昔单抗、那他珠单抗与普通人群之间浸润性癌症风险无差异。
  • 芬戈莫德相较普通人群风险可能更高(HR=1.53,95%CI 0.98-2.38),相较利妥昔单抗亦可能更高(HR=1.68,95%CI 1.00-2.84)。

临床怎么用

  • 为多发性硬化患者选择高效疾病修饰治疗时,可将利妥昔单抗和那他珠单抗相较普通人群未见的浸润性癌症风险升高纳入安全讨论。
  • 对使用芬戈莫德的患者,可结合其相较普通人群和利妥昔单抗的边缘显著性风险升高,个体化权衡并保持癌症监测意识。

局限性

  • 芬戈莫德相关风险为边缘显著性,且无法归因于任何特定类型癌症。
  • 作者指出需进一步研究验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Novel, highly effective disease-modifying therapies have revolutionized multiple sclerosis (MS) care. However, evidence from large comparative studies on important safety outcomes, such as cancer, is still lacking. METHODS: In this nationwide register-based cohort study, we linked data from the Swedish MS register to the Swedish Cancer Register and other national health care and census registers. We included 4,187 first-ever initiations of rituximab, 1,620 of fingolimod, and 1,670 of natalizumab in 6,136 MS patients matched for age, sex, and location to 37,801 non-MS general population subjects. Primary outcome was time to first invasive cancer. RESULTS: We identified 78 invasive cancers among treated patients: rituximab 33 (incidence rate [IR] per 10,000 person-years = 34.4, 95% confidence interval [CI] = 23.7-48.3), fingolimod 28 (IR = 44.0, 95% CI = 29.2-63.5), and natalizumab 17 (IR = 26.0, 95% CI = 15.1-41.6). The general population IR was 31.0 (95% CI = 27.8-34.4). Adjusting for baseline characteristics, we found no difference in risk of invasive cancer between rituximab, natalizumab, and the general population but a possibly higher risk with fingolimod compared to the general population (hazard ratio [HR] = 1.53, 95% CI = 0.98-2.38) and rituximab (HR = 1.68, 95% CI = 1.00-2.84). INTERPRETATION: In this first large comparative study of 3 highly effective MS disease-modifying therapies, no increased risk of invasive cancer was seen with rituximab and natalizumab, compared to the general population. However, there was a borderline-significant increased risk with fingolimod, compared to both the general population and rituximab. It was not possible to attribute this increased risk to any specific type of cancer, and further studies are warranted to validate these findings. ANN NEUROL 2020;87:688-699.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Alping P, Askling J, Burman J, et al. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020. PMID: 32056253. doi:10.1002/ana.25701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。